Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease

An extended release form of the cholinesterase inhibitor (ChEI) drug galantamine (galantamine-ER) was developed, chiefly to increase adherence to medication regimes in patients with mild-to-moderate Alzheimer’s disease (AD). Except for predicted differences in (C(max)) and t(max), comparable doses o...

Descripción completa

Detalles Bibliográficos
Autor principal: Seltzer, Ben
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2817936/
https://www.ncbi.nlm.nih.gov/pubmed/20169037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2817936/
https://www.ncbi.nlm.nih.gov/pubmed/20169037

Ejemplares similares